January 16, 2014
1 min read

Ivantis raises $46.5 million in Series B funding

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Ivantis has secured an additional $14 million from Vertex Ventures and GBS Ventures in the final close of its Series B financing, bringing the total amount raised to $46.5 million, according to a press release.

The funds will support the company’s three large ongoing clinical trials, including the U.S. pivotal trial of the Hydrus microstent.

The Hydrus, designed to reduce IOP by re-establishing the patient’s natural outflow pathway, is about the size of an eyelash and placed through a minimally invasive microsurgical procedure, according to the release.